HomeTrialNCT07345494
🔬NCT07345494RECRUITING

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Study Summary

The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment50 participants
Primary Completion
Lead SponsorAscendis Pharma A/S
Data Retrieved2026-04-11 02:54:40.919410+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.